Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5LFYN)

Drug Name
alpha-ketoglutaric acid Drug Info
Synonyms 2-ketoglutarate; 2-oxoglutarate; alpha-ketoglutarate; 2-ketoglutaric acid; oxoglutarate
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
51
ChEBI ID
CHEMBL1686
CAS Number
CAS 328-50-7
TTD Drug ID
DM5LFYN
VARIDT Drug ID
DR00139
INTEDE Drug ID
DR2059

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
DOT
Drug Status:
Investigative Drug(s)
Preclinical Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Oxoglutarate receptor (OXGR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LTE4 DMCPB0Q Discovery agent N.A. Investigative [14]
Drug(s) Transported By Sodium/dicarboxylate cotransporter 3 (SLC13A3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dicarboxylate DML3HEM N. A. N. A. Investigative [5]
Succinate DMPY09A N. A. N. A. Investigative [5]
Drug(s) Transported By Sodium-coupled citrate transporter (SLC13A5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Citrate DM37NYK N. A. N. A. Preclinical [6]
Succinate DMPY09A N. A. N. A. Investigative [6]
Drug(s) Transported By Mitochondrial 2-oxodicarboxylate carrier (SLC25A21)
Drug Name Drug ID Indication ICD 11 Highest Status REF
alpha-oxoadipic acid DM0KXN4 Discovery agent N.A. Investigative [3]
Drug(s) Metabolized By Prolyl 4-hydroxylase alpha-2 (P4HA2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vitamin C DMXJ7O8 Adenocarcinoma 2D40 Approved [7]
Drug(s) Metabolized By Prolyl 4-hydroxylase alpha-1 (P4HA1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vitamin C DMXJ7O8 Adenocarcinoma 2D40 Approved [7]
Drug(s) Metabolized By HIF-prolyl hydroxylase 2 (EGLN1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vitamin C DMXJ7O8 Adenocarcinoma 2D40 Approved [8]
Drug(s) Metabolized By Prolyl 4-hydroxylase alpha-3 (P4HA3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vitamin C DMXJ7O8 Adenocarcinoma 2D40 Approved [11]
Drug(s) Affected By Collagen alpha-1(I) chain (COL1A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Penicillamine DM40EF6 Cystinuria 5C60.2 Approved [15]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [16]
Diazepam DM08E9O Alcohol withdrawal Approved [17]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [18]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [19]
Methotrexate DM2TEOL Anterior urethra cancer Approved [20]
Ceruletide DM2WE5K Caerulein stimulated gastric and pancreatic secretion 5A4Y Approved [21]
Dactinomycin DM2YGNW Adult kidney Wilms tumor Approved [22]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [23]
Quercetin DM3NC4M Obesity 5B81 Approved [24]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Osteocalcin (BGLAP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [25]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [26]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [19]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [27]
Quercetin DM3NC4M Obesity 5B81 Approved [28]
Glucosamine DM4ZLFD Osteoarthritis FA00-FA05 Approved [29]
Pamidronate DMB4AVP Bone Paget disease Approved [30]
Falecalcitrol DMBI9ZJ Hyperparathyroidism 5A51 Approved [31]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [32]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [33]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Integrin-binding sialoprotein (IBSP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [34]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [35]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [36]
Calcidiol DMN4CV5 Hypophosphatemia Approved [35]
Magnesium DMU4ORS Ischemic stroke 8B11.5Z Approved [37]
Vitamin C DMXJ7O8 Adenocarcinoma 2D40 Approved [38]
Camptothecin DM6CHNJ Solid tumour/cancer 2A00-2F9Z Phase 3 [39]
GSK2816126 DMJDVW4 Solid tumour/cancer 2A00-2F9Z Phase 1 [40]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [41]
EUGENOL DM7US1H Discovery agent N.A. Patented [42]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Small ribosomal subunit protein eS6 (RPS6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [43]
Methotrexate DM2TEOL Anterior urethra cancer Approved [44]
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [45]
Glucosamine DM4ZLFD Osteoarthritis FA00-FA05 Approved [46]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [47]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [48]
Testosterone DM7HUNW Hot flushes GA30 Approved [49]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [50]
Capivasertib DM9SKW8 Breast cancer 2C60-2C65 Approved [51]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [52]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Transcription factor Sp7 (SP7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [26]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [53]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [54]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [55]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [56]
Berberine DMC5Q8X N. A. N. A. Phase 4 [57]
Resveratrol DM3RWXL Giant cell arteritis 4A44.2 Phase 3 [56]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [41]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [58]
PD98059 DMZC90M Cardiac arrest MC82 Investigative [56]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By D-2-hydroxyglutarate dehydrogenase, mitochondrial (D2HGDH)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [55]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [59]
Arsenic DMTL2Y1 N. A. N. A. Approved [60]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [61]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [41]
PMID28460551-Compound-2 DM4DOUB N. A. N. A. Patented [62]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [63]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Oxoglutarate receptor (OXGR1) TTAS1QK OXGR1_HUMAN Agonist [2]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Mitochondrial 2-oxodicarboxylate carrier (SLC25A21) DT2UQYR ODC_HUMAN Substrate [3]
Mitochondrial 2-oxoglutarate/malate carrier (SLC25A11) DT0YAUQ M2OM_HUMAN Substrate [4]
Sodium/dicarboxylate cotransporter 3 (SLC13A3) DTKXTPW S13A3_HUMAN Substrate [5]
Sodium-coupled citrate transporter (SLC13A5) DTFPWJ9 S13A5_HUMAN Substrate [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Prolyl 4-hydroxylase alpha-1 (P4HA1) DESO5ZY P4HA1_HUMAN Substrate [7]
Prolyl 4-hydroxylase alpha-2 (P4HA2) DE5EGK0 P4HA2_HUMAN Substrate [7]
HIF-prolyl hydroxylase 3 (EGLN3) DEMQTKH EGLN3_HUMAN Substrate [8]
HIF-prolyl hydroxylase 2 (EGLN1) DEWO724 EGLN1_HUMAN Substrate [8]
Factor inhibiting HIF-1 (HIF1AN) DEY1CBW HIF1N_HUMAN Substrate [9]
Prolyl 3-hydroxylase 1 (P3H1) DEW527E P3H1_HUMAN Substrate [10]
Prolyl 3-hydroxylase 2 (P3H2) DELB5PA P3H2_HUMAN Substrate [10]
Prolyl 4-hydroxylase alpha-3 (P4HA3) DE2L4RX P4HA3_HUMAN Substrate [11]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Gene/Protein Processing [12]
D-2-hydroxyglutarate dehydrogenase, mitochondrial (D2HGDH) OTLHXW69 D2HDH_HUMAN Biotransformations [13]
Integrin-binding sialoprotein (IBSP) OT29944Y SIAL_HUMAN Gene/Protein Processing [12]
Osteocalcin (BGLAP) OTK1YLWQ OSTCN_HUMAN Gene/Protein Processing [12]
Small ribosomal subunit protein eS6 (RPS6) OTT4D1LN RS6_HUMAN Post-Translational Modifications [12]
Transcription factor Sp7 (SP7) OT07ETZT SP7_HUMAN Gene/Protein Processing [12]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3636).
2 Screening beta-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. J Biomol Screen. 2013 Jun;18(5):599-609.
3 Mitochondrial oxodicarboxylate carrier deficiency is associated with mitochondrial DNA depletion and spinal muscular atrophy-like disease. Genet Med. 2018 Oct;20(10):1224-1235.
4 The mitochondrial dicarboxylate and 2-oxoglutarate carriers do not transport glutathione. FEBS Lett. 2015 Feb 27;589(5):621-8.
5 SLC13A3 variants cause acute reversible leukoencephalopathy and -ketoglutarate accumulation. Ann Neurol. 2019 Mar;85(3):385-395.
6 SLC13 family of Na+ coupled di- and tri-carboxylate/sulfate transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):299-312.
7 Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis. Matrix Biol. 2003 Mar;22(1):15-24.
8 Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem. 2003 Aug 15;278(33):30772-80.
9 The facial triad in the alpha-ketoglutarate dependent oxygenase FIH: a role for sterics in linking substrate binding to O2 activation. J Inorg Biochem. 2017 Jan;166:26-33.
10 Characterization of recombinant human prolyl 3-hydroxylase isoenzyme 2, an enzyme modifying the basement membrane collagen IV. J Biol Chem. 2008 Jul 11;283(28):19432-9.
11 Identification and characterization of a third human, rat, and mouse collagen prolyl 4-hydroxylase isoenzyme. J Biol Chem. 2003 Nov 28;278(48):47685-93.
12 Alpha ketoglutarate exerts a pro-osteogenic effect in osteoblast cell lines through activation of JNK and mTOR/S6K1/S6 signaling pathways. Toxicol Appl Pharmacol. 2019 Jul 1;374:53-64.
13 Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria. Am J Hum Genet. 2005 Feb;76(2):358-60. doi: 10.1086/427890. Epub 2004 Dec 17.
14 Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand. J Biol Chem. 2013 Apr 19;288(16):10967-72.
15 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
16 Investigation of in vitro odonto/osteogenic capacity of cannabidiol on human dental pulp cell. J Dent. 2021 Jun;109:103673. doi: 10.1016/j.jdent.2021.103673. Epub 2021 Apr 16.
17 Patterns of some extracellular matrix gene expression are similar in cells from cleft lip-palate patients and in human palatal fibroblasts exposed to diazepam in culture. Toxicology. 2009 Mar 4;257(1-2):10-6. doi: 10.1016/j.tox.2008.12.002. Epub 2008 Dec 9.
18 Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
19 Protective effects of myricitrin against osteoporosis via reducing reactive oxygen species and bone-resorbing cytokines. Toxicol Appl Pharmacol. 2014 Nov 1;280(3):550-60.
20 Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
21 Acinar cell-specific knockout of the PTHrP gene decreases the proinflammatory and profibrotic responses in pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2014 Sep 1;307(5):G533-49. doi: 10.1152/ajpgi.00428.2013. Epub 2014 Jul 17.
22 The effects of particulate wear debris, cytokines, and growth factors on the functions of MG-63 osteoblasts. J Bone Joint Surg Am. 2001 Feb;83(2):201-11. doi: 10.2106/00004623-200102000-00007.
23 Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. Arthritis Rheum. 2006 Apr;54(4):1298-308. doi: 10.1002/art.21723.
24 Antifibrotic effects of quercetin in primary orbital fibroblasts and orbital fat tissue cultures of Graves' orbitopathy. Invest Ophthalmol Vis Sci. 2012 Aug 31;53(9):5921-9. doi: 10.1167/iovs.12-9646.
25 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines. Anticancer Res. 1999 May-Jun;19(3A):1689-97.
26 Cannabidiol induces osteoblast differentiation via angiopoietin1 and p38 MAPK. Environ Toxicol. 2020 Dec;35(12):1318-1325. doi: 10.1002/tox.22996. Epub 2020 Jul 13.
27 The effect of simvastatin on the proliferation and differentiation of human bone marrow stromal cells. J Korean Med Sci. 2005 Jun;20(3):438-44. doi: 10.3346/jkms.2005.20.3.438.
28 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
29 Glucosamine promotes osteogenic differentiation of dental pulp stem cells through modulating the level of the transforming growth factor-beta type I receptor. J Cell Physiol. 2010 Oct;225(1):140-51.
30 Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment. Calcif Tissue Int. 2001 May;68(5):285-90.
31 A highly potent 26,27-Hexafluoro-1a,25-dihydroxyvitamin D3 on calcification in SV40-transformed human fetal osteoblastic cells. Calcif Tissue Int. 2002 Jun;70(6):488-95.
32 Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. J Cell Biochem. 2007 Aug 15;101(6):1430-8. doi: 10.1002/jcb.21259.
33 Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol. 2014 Mar 17;27(3):408-20.
34 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
35 Effects of 25-hydroxyvitamin D(3) on proliferation and osteoblast differentiation of human marrow stromal cells require CYP27B1/1alpha-hydroxylase. J Bone Miner Res. 2011 May;26(5):1145-53.
36 Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition. Biochem J. 2004 Dec 15;384(Pt 3):591-8. doi: 10.1042/BJ20040380.
37 Effect of surface chemical modification of bioceramic on phenotype of human bone-derived cells. J Biomed Mater Res. 1999 Mar 15;44(4):389-96. doi: 10.1002/(sici)1097-4636(19990315)44:4<389::aid-jbm4>3.0.co;2-o.
38 Potential osteoinductive effects of calcitriol on the m-RNA of mesenchymal stem cells derived from human alveolar periosteum. Biomed Res Int. 2016;2016:3529561.
39 ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014 Dec 1;74(23):6968-79.
40 Epigenetic control of skeletal development by the histone methyltransferase Ezh2. J Biol Chem. 2015 Nov 13;290(46):27604-17.
41 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
42 Cytotoxic effect of eugenol on the expression of molecular markers related to the osteogenic differentiation of human dental pulp cells. Odontology. 2011 Jul;99(2):188-92. doi: 10.1007/s10266-011-0009-2. Epub 2011 Jun 26.
43 Cannabidiol Reduces Leukemic Cell Size - But Is It Important?. Front Pharmacol. 2017 Mar 24;8:144. doi: 10.3389/fphar.2017.00144. eCollection 2017.
44 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
45 Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des. 2011 Dec;78(6):999-1005. doi: 10.1111/j.1747-0285.2011.01239.x. Epub 2011 Oct 31.
46 D-glucosamine down-regulates HIF-1alpha through inhibition of protein translation in DU145 prostate cancer cells. Biochem Biophys Res Commun. 2009 Apr 24;382(1):96-101. doi: 10.1016/j.bbrc.2009.02.129. Epub 2009 Feb 28.
47 Proteomics-based identification of differentially abundant proteins from human keratinocytes exposed to arsenic trioxide. J Proteomics Bioinform. 2014 Jul;7(7):166-178.
48 Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling. Aging (Albany NY). 2012 Dec;4(12):952-65. doi: 10.18632/aging.100521.
49 Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival. Anticancer Res. 2010 Oct;30(10):3895-901.
50 Imatinib disturbs lysosomal function and morphology and impairs the activity of mTORC1 in human hepatocyte cell lines. Food Chem Toxicol. 2022 Apr;162:112869. doi: 10.1016/j.fct.2022.112869. Epub 2022 Feb 16.
51 Inhibition of cholesterol metabolism underlies synergy between mTOR pathway inhibition and chloroquine in bladder cancer cells. Oncogene. 2016 Aug 25;35(34):4518-28. doi: 10.1038/onc.2015.511. Epub 2016 Feb 8.
52 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
53 Naringin protects human adipose-derived mesenchymal stem cells against hydrogen peroxide-induced inhibition of osteogenic differentiation. Chem Biol Interact. 2015 Dec 5;242:255-61. doi: 10.1016/j.cbi.2015.10.010. Epub 2015 Oct 19.
54 Small ubiquitin-related modifier-1 modification regulates all-trans-retinoic acid-induced differentiation via stabilization of retinoic acid receptor . FEBS J. 2014 Jul;281(13):3032-47. doi: 10.1111/febs.12840. Epub 2014 Jun 2.
55 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
56 Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. Phytomedicine. 2007 Dec;14(12):806-14. doi: 10.1016/j.phymed.2007.04.003. Epub 2007 Aug 8.
57 Berberine promotes bone marrow-derived mesenchymal stem cells osteogenic differentiation via canonical Wnt/-catenin signaling pathway. Toxicol Lett. 2016 Jan 5;240(1):68-80. doi: 10.1016/j.toxlet.2015.10.007. Epub 2015 Oct 22.
58 Repercussions of Bisphenol A on the Physiology of Human Osteoblasts. Int J Mol Sci. 2022 May 11;23(10):5349. doi: 10.3390/ijms23105349.
59 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
60 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
61 Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013 Mar;3(3):308-23.
62 Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
63 Alternatives for the worse: Molecular insights into adverse effects of bisphenol a and substitutes during human adipocyte differentiation. Environ Int. 2021 Nov;156:106730. doi: 10.1016/j.envint.2021.106730. Epub 2021 Jun 27.